Recent 8-K filings for PPCB
Highest-materiality recent filing
Nasdaq notifies Propanc Biopharma of non-compliance with $1.00 minimum bid price rule
- Notice received Dec 31, 2025; bid price below $1.00 for 35 consecutive business days.
- Compliance deadline June 30, 2026; must close at $1.00+ for 10 consecutive days.
-
Annie Van Broekhoven retired from Board effective July 8, 2026.
-
Propanc Biopharma board changes: Kenyon retires, Brandt appointed
Dr. Julian Kenyon retired from Board on Feb 20, 2026; remains as medical advisor.
-
Nasdaq notifies Propanc Biopharma of non-compliance with $1.00 minimum bid price rule
Notice received Dec 31, 2025; bid price below $1.00 for 35 consecutive business days.
-
Propanc Biopharma closes $1.0M private placement of Series C Preferred Stock to Hexstone Capital
Hexstone purchased 100 Series C Preferred shares at $10,000 each plus a warrant for up to 9,900 additional shares; total cash $1,000,099.
-
Propanc Biopharma enters Series C Preferred Stock financing with Hexstone Capital
Issues 100 shares of Series C Preferred convertible at lesser of $5.00 fixed or 85% of lowest trading price over conversion period.
-
Propanc Biopharma prices $4M public offering, uplists to Nasdaq; appoints two independent directors
Raised $4M gross ($3.34M net) via public offering of 1M shares at $4.00/sh; underwriters have 45-day option for 150K more.
-
Propanc Biopharma appoints Jeannine Zimmerman as CFO effective Aug 13, 2025
Jeannine Zimmerman, age 48, appointed CFO effective August 13, 2025.
-
Propanc Biopharma enters $112,350 convertible note at 22% interest with 1800 Diagonal Lending
Issued $112,350 convertible promissory note to 1800 Diagonal Lending LLC at a 22% annual interest rate.
-
Propanc Biopharma issues $82,500 promissory note to accredited investor
Principal amount $82,500; purchase price $75,000; 10% annual interest.
-
Principal $67,860 for net $58,000; matures Apr 16, 2026; 15% one-time interest.
-
Propanc Biopharma enters $25K convertible note and $13K AUD loan for working capital
Issued $25,000 convertible note to Geebis Consulting at 8% interest; maturity June 2026; conversion price $5.00.
-
Propanc Biopharma issues $60,000 promissory note to accredited investor
Principal amount $60,000; purchase price $50,000 (implicit $10,000 discount).
-
Propanc Biopharma issues $90K promissory note and extends maturity of old note to June 15, 2025
Issued $90,000 principal promissory note at 10% interest for $75,000 purchase price; matures June 15, 2025.
-
Propanc Biopharma raises ~$180k via convertible notes and board loan; conversion at deep discounts
$55k face convertible note issued at $50k (original issue discount) to GS Capital Partners; conversion price $5.00, drops to $2.50 if stock below $4 for 5 days.
-
Propanc Biopharma issues $33K convertible note to GS Capital Partners for working capital
Convertible promissory note with $33,000 principal, purchased at $30,000 (original issue discount of $3,000).
-
Propanc Biopharma raises $108K in two convertible note financings in Feb 2025
$65,000 convertible note (purchase price $56,000) issued Feb 6; 15% flat interest, maturity Nov 30, 2025.
-
Propanc Biopharma raises ~$61k via two convertible notes with dilutive terms
Dec 16 note: $22k principal ($20k proceeds), 8% interest, matures June 15, 2025; convertible at $0.0003/share (step-down to $0.0001).
-
Propanc Biopharma enters $175K AUD loan with Aggro Investments at 12% interest
Loan principal $175,000 AUD from Aggro Investments Pty Ltd, due in 4 months or less at company's discretion.
-
Propanc Biopharma issues $33K convertible note; due March 2025, conversion at $0.0003
Issued convertible promissory note with $33,000 principal ($30,000 net) to GS Capital Partners, LLC.
-
Propanc Biopharma enters $85K AUD loan from board member for working capital
Effective August 26, 2024, company entered loan agreement with a board member for $85,000 AUD.
-
Propanc Biopharma issues $33K convertible promissory note to GS Capital at 8% interest
Company entered securities purchase agreement with GS Capital Partners on Aug 9, 2024 for $33,000 principal note at $30,000 purchase price.
-
Propanc Biopharma enters $150K AUD loan agreement with 12% interest, due Nov 2024
Loan of $150,000 AUD effective Aug 1, 2024, with maturity Nov 1, 2024.
-
Propanc Biopharma issues $33,750 convertible note with 35% discount for working capital
Issued convertible promissory note to 104 LLC for gross proceeds of $30,375 after $2,500 legal fee deduction.
-
Propanc Biopharma raises $41K via convertible note with 35% discount conversion
Issued $49,200 convertible promissory note to 1800 Diagonal Lending LLC for $41,000, net proceeds for working capital.
-
Propanc Biopharma enters two loan agreements totaling AUD $120,000 at 12% interest
First loan of AUD $20,000 on June 3, 2024; 12% annual interest; matures June 3, 2025.
-
Propanc Biopharma enters loans totaling $120K AUD at 12% interest
First loan of $20,000 AUD on June 3, 2024, at 12% annual interest, maturing June 3, 2025.
-
Propanc Biopharma closes $49,200 convertible note financing with 15% interest, net $41,000
Entered securities purchase agreement with 1800 Diagonal Lending LLC for $49,200 convertible note; purchase price $41,000 (includes $8,200 OID).
-
Propanc Biopharma extends $177,980 note maturity to Sept 30, 2024
Maturity of 10% OID Promissory Note with Ionic Ventures extended from Nov 15, 2023 to Sept 30, 2024.
-
Propanc Biopharma issues $27,500 convertible note to GS Capital Partners
Entered into securities purchase agreement; note principal $27,500 at $25,000 purchase price (original issue discount).
-
Propanc Biopharma updates corporate presentation; no material specifics disclosed in filing
Filing states company updated its corporate overview and company presentation.
-
Propanc Biopharma raises $46,875 via convertible note at 35% discount and 8% interest
Principal amount $50,000; purchase price $46,875; net proceeds for working capital.
-
Principal $150K; purchase price $135K (15% OID); 10% interest; maturity Dec 8, 2024.
-
Propanc Biopharma issues $45K convertible note with 35% discount conversion
Principal $45,000; maturity Sept 15, 2024; interest 8% (22% default); issued to 1800 Diagonal Lending LLC.
-
Propanc Biopharma closes $40K convertible note with investor
Closed sale of $40K convertible promissory note to an investor on Oct 29, 2023.
-
Propanc Biopharma issues $40K convertible note to 1800 Diagonal Lending
Principal $40,000, convertible at 65% of lowest three trading prices in prior ten trading days.
-
Entered securities purchase agreement with GS Capital Partners, LLC for $61,000 principal convertible note at 8% interest.
-
Propanc Biopharma raises $72,500 via convertible note with aggressive conversion terms
$77,500 convertible note issued to GS Capital Partners; net proceeds $72,500, 8% interest, matures Feb 2024.
-
Propanc Biopharma enters $55K convertible note and $132K promissory note financings
Issued $55,000 convertible promissory note to 1800 Diagonal Lending LLC, convertible at 65% of market price after 180 days, 8% interest, matures Aug 16, 2024.
-
Propanc Biopharma issues $45K convertible note at 65% discount; terminates $5M equity line
Issued $45,000 convertible promissory note to 1800 Diagonal Lending LLC, convertible at 65% of market price after 180 days.
-
Propanc Biopharma enters $5M equity line with Dutchess Capital at 85% discount
Up to $5M of common stock sales over 24 months; purchase price 85% of lowest trading price during 7-day pricing period.
-
Propanc Biopharma secures $65K convertible note and AU$230K loan; issues warrant for 15M shares
Entered securities purchase agreement with 1800 Diagonal Lending LLC for $65,000 convertible note at 8% interest, convertible at 65% of market price.
-
Propanc Biopharma defaults on $125K convertible note; enters $5M equity facility
Entered equity line facility for up to $5M over 36 months; shares sold at 80% of lowest VWAP.
-
Propanc Biopharma effects 1-for-1000 reverse stock split effective May 1, 2023
Reverse stock split ratio 1-for-1000, effective May 1, 2023.
-
Propanc Biopharma retires all Series A Preferred Stock; no shares outstanding
Filed Certificate of Retirement with Delaware to eliminate Series A Preferred Stock from charter.
-
Propanc Biopharma retires final convertible note via full conversion to common stock
Retired final convertible promissory note dated June 30, 2022, with 1800 Diagonal Lending LLC.
-
Propanc Biopharma issues $111,111 convertible note to ONE44 Capital LLC
Principal $111,111; net proceeds $100,000 after $11,111 original issue discount.
-
Propanc Biopharma enters amended employment agreement with CEO James Nathanielsz
New base salary of $600,000 AUD per annum, plus salary sacrifice for tuition up to $200,000 AUD.
-
Propanc Biopharma issues $53,750 convertible note to Red Road with 35% discount conversion
Principal $53,750, net proceeds $50,000 after $3,750 fees; maturity Oct 6, 2023; 8% interest.
-
Propanc Biopharma issues $71,500 convertible note to GS Capital
Principal $71,500 with $4,000 OID; net proceeds $67,500 for general working capital.
-
Propanc Biopharma raises $203K via convertible notes with dilutive conversion terms
Entered convertible note agreements with GS Capital ($93K principal, net $88K after $5K OID) and ONE44 ($110K principal, net $100K after $10K OID).
Materiality & sentiment trend
Max materiality 0.75 · Median 0.45 · Most common event debt